GLP-1 weight loss medications are here to stay, theres no questioning that
Barriers to initiating treatment may include delayed recognition of obesity as a disease by public health and medical organizations, provider biases regarding patients with obesity, lack of reimbursement leading to out-of-pocket costs to patients, inadequate training of providers, historical safety issues with AOMs, and perceptions of patients and their caregivers regarding the efficacy of AOMs [14,15,16,17]
These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education
Serious symptoms such as allergic reactions or irregular heartbeat require immediate care
This results in more sustainable improvements with fewer side effects compared to traditional hormone therapies